US 10,266,815 B2Granted

Compositions and methods for treating celiac sprue disease

AssigneeUniversity of Washington through its Center for Commercialization

InventorsJustin Bloomfield Siegel, David Baker, Ingrid Swanson Pultz

Life of this patent

Estimating the term…

Abstract

The invention provides compositions and methods for treating celiac sprue.

Claims18

Dependent claims

A composition, comprising

(a) one or more polypeptides comprising the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs:
74-77, 79-89, 95, 97-99, and 102-111, or processed versions thereof;
and
(b) one or more further polypeptides comprising an amino acid sequence selected from the group consisting of:
(A) an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:35, wherein
(i) the polypeptide of (A) degrades a PQPQLP (SEQ ID NO:34) peptide at pH 4;
and
(ii) residue 278 is Ser, residue 78 is Glu, and residue 82 is Asp
(B) an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, wherein
(i) the polypeptide of (B) degrades a PQPQLP (SEQ ID NO:34) peptide at pH 4;
and
(ii) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp.

9 more elements

An isolated polypeptide selected from the group consisting of a polypeptide comprising the amino acid sequence of a polypeptide selected from the following group, or processed versions thereof:

(a) SEQ ID NO:
95, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) amino acid (AA) residue 116 is V or D;
(ii) AA residue 255 is S, K, or G;
(iii) AA residue 284 is D;
(iv) AA residue 285 is T;
(v) AA residue 286 is A, T, or N;
(vi) AA residue 312 is S;
(vii) AA residue 347 is N;
(viii) AA residue 350 is T or A;
(ix) AA residue 351 is N or G;
(x) AA residue 354 is D;
and (xi) AA residue 361 is S or H;
(b) SEQ ID NO:
75, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 106 is D;
(ii) AA residue 246 is S, K, or G;
(iii) AA residue 275 is D;
(iv) AA residue 276 is S;
(v) AA residue 277 is A, T, or N;
(vi) AA residue 303 is S;
(vii) AA residue 338 is S;
(viii) AA residue 341 is T or A;
(ix) AA residue 342 is N or G;
(x) AA residue 345 is Q or D;
and (xi) AA residue 352 is S or H;
(c) SEQ ID NO:
76, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 120 is D;
(ii) AA residue 259 is S, K, or G;
(iii) AA residue 288 is D;
(iv) AA residue 289 is T;
(v) AA residue 290 is A, T, or N;
(vi) AA residue 316 is S;
(vii) AA residue 351 is S or N;
(viii) AA residue 354 is A;
(ix) AA residue 355 is N or G;
(x) AA residue 358 is D;
and (xi) AA residue 365 is S or H;
(d) SEQ ID NO:
79, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 107 is V or D;
(ii) AA residue 245 is S, K, or G;
(iii) AA residue 274 is D;
(iv) AA residue 275 is T;
(v) AA residue 276 is A, T, or N;
(vi) AA residue 302 is S;
(vii) AA residue 337 is S or N;
(viii) AA residue 340 is T or A;
(ix) AA residue 341 is N or G;
(x) AA residue 344 is Q or D;
and (xi) AA residue 351 is S or H;
(e) SEQ ID NO:
80, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 76 is V or D;
(ii) AA residue 206 is S, K, or G;
(iii) AA residue 235 is D;
(iv) AA residue 236 is S;
(v) AA residue 237 is A, T, or N;
(vi) AA residue 262 is S;
(vii) AA residue 297 is S or N;
(viii) AA residue 300 is T or A;
(ix) AA residue 301 is N or G;
(x) AA residue 302 is Q or D;
and (xi) AA residue 309 is S or H;
(f) SEQ ID NO:
81, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 105 is D;
(ii) AA residue 244 is S or K;
(iii) AA residue 272 is D;
(iv) AA residue 273 is S;
(v) AA residue 274 is A, T, or N;
(vi) AA residue 299 is S;
(vii) AA residue 334 is N;
(viii) AA residue 337 is T or A;
(ix) AA residue 338 is N or G;
(x) AA residue 341 is Q or D;
and (xi) AA residue 348 is S or H;
(g) SEQ ID NO:
82, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 106 is V or D;
(ii) AA residue 244 is S, K, or G;
(iii) AA residue 273 is D;
(iv) AA residue 274 is T;
(v) AA residue 275 is A, T, or N;
(vi) AA residue 301 is S;
(vii) AA residue 336 is N;
(viii) AA residue 339 is T or A;
(ix) AA residue 340 is N or G;
(x) AA residue 343 is D;
and (xi) AA residue 350 is S or H;
(h) SEQ ID NO:
83, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 107 is V or D;
(ii) AA residue 245 is S, K, or G;
(iii) AA residue 274 is D;
(iv) AA residue 275 is T;
(v) AA residue 276 is A, T, or N;
(vi) AA residue 302 is S;
(vii) AA residue 337 is N;
(viii) AA residue 340 is T or A;
(ix) AA residue 341 is N or G;
(x) AA residue 344 is Q or D;
and (xi) AA residue 351 is S or H;
(i) SEQ ID NO:
84, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 104 is V or D;
(ii) AA residue 241 is S, K, or G;
(iii) AA residue 270 is D;
(iv) AA residue 271 is S;
(v) AA residue 272 is D, A, T, or N;
(vi) AA residue 398 is S;
(vii) AA residue 33 is S;
(viii) AA residue 336 is A;
(ix) AA residue 337 is N or G;
(x) AA residue 340 is D;
and (xi) AA residue 347 is S or H;
(j) SEQ ID NO:
85, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 104 is D;
(ii) AA residue 245 is S, K, or G;
(iii) AA residue 274 is D;
(iv) AA residue 275 is S;
(v) AA residue 276 is A, T, or N;
(vi) AA residue 302 is S;
(vii) AA residue 337 is S or N;
(viii) AA residue 340 is T or A;
(ix) AA residue 341 is N or G;
(x) AA residue 344 is Q or D;
and (xi) AA residue 351 is S or H;
(k) SEQ ID NO:
86, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 118 is V or D;
(ii) AA residue 250 is K, or G;
(iii) AA residue 279 is D;
(iv) AA residue 280 is S;
(v) AA residue 281 is A, T, or N;
(vi) AA residue 307 is S;
(vii) AA residue 342 is S or N;
(viii) AA residue 345 is A;
(ix) AA residue 346 is N or G;
(x) AA residue 349 is Q or D;
and (xi) AA residue 356 is S or H;
(l) SEQ ID NO:
87, wherein one, two, three, four, five, six, seven, eight, nine, ten, or all eleven of the following are true:
(i) AA residue 121 is V or D;
(ii) AA residue 253 is S, K, or G;
(iii) AA residue 282 is D;
(iv) AA residue 283 is S;
(v) AA residue 284 is A, T, or N;
(vi) AA residue 310 is S;
(vii) AA residue 345 is S;
(viii) AA residue 348 is T or A;
(ix) AA residue 349 is N or G;
(x) AA residue 352 is Q or D;
and (xi) AA residue 357 is S or H;
and
(m) SEQ ID NO:
88, wherein one, two, three, four, five, six, seven, eight, nine, or all ten of the following are true:
(i) AA residue 111 is S, K, or G;
(ii) AA residue 139 is D;
(iii) AA residue 140 is T or S;
(iv) AA residue 141 is D, A, T, or N;
(v) AA residue 164 is S;
(vi) AA residue 199 is S or N;
(vii) AA residue 202 is T or A;
(viii) AA residue 203 is N or G;
(ix) AA residue 204 is Q or D;
and (x) AA residue 211 is S or H.

166 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/911,630Filed 13 Aug 2014 · us provisional application
Priority: 14 Aug 2013
Published: US 2016/0194621 A17 Jul 2016
Granted: 23 Apr 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

C12N 9/52
Proteinases , e.g. Endopeptidases: derived from bacteria or Archaea
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61P 37/00
Drugs for immunological or allergic disorders

Family

Application61/865,787Us provisional application · filed 14 Aug 2013
US 2016/0194621 A1Pre-grant publication · published 7 Jul 2016
US 10,266,815 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Facts

Application

14/911,630Filed 13 Aug 2014 · us provisional application

Priority

14 Aug 2013

Published

US 2016/0194621 A17 Jul 2016

Granted

23 Apr 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

C12N 9/52
Proteinases , e.g. Endopeptidases: derived from bacteria or Archaea
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 29/00
Non-central analgesic, antipyretic or antiinflammatory agents
A61P 37/00
Drugs for immunological or allergic disorders